Integrin alpha-4/beta-1 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Integrin alpha-4/beta-1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P05556. Start with multiple sclerosis, then reuse UniProt P05556 as the stable protein anchor across project notes and exports.
Start with multiple sclerosis, then reuse UniProt P05556 as the stable protein anchor across project notes and exports.
Integrin alpha-4/beta-1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include FIRATEGRAST, NATALIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyIntegrin beta-1
Review this target as Integrin alpha-4/beta-1, mapped to UniProt P05556. ChEMBL maps the protein component as Integrin beta-1. Sequence length is 798 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Integrin alpha-4/beta-1 as ChEMBL target CHEMBL1907599, mapped to UniProt P05556. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Integrin alpha-4/beta-1 is the right protein anchor across sources, using UniProt P05556 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why multiple sclerosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Integrin alpha-4/beta-1 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P05556 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Integrin beta-1 |
| UniProt Accession | P05556 |
| Component Type | Protein |
| Sequence Length | 798 aa |
Integrin beta-1
Review this target as Integrin alpha-4/beta-1, mapped to UniProt P05556. ChEMBL maps the protein component as Integrin beta-1. Sequence length is 798 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Integrin alpha-4/beta-1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.
Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include FIRATEGRAST, NATALIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL569442 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL1241140 | 10.66 | IC50 | 0.022 | Preclinical |
| CHEMBL296804 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL566154 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL395150 | 10.43 | IC50 | 0.0372 | Preclinical |
| CHEMBL447509 | 10.43 | IC50 | 0.037 | Preclinical |
| CHEMBL2110195 | 10.3 | IC50 | 0.05 | Preclinical |
| CHEMBL69035 | 10.3 | IC50 | 0.05 | Preclinical |
| CHEMBL505769 | 10.28 | IC50 | 0.0525 | Preclinical |
| CHEMBL1829034 | 10.15 | IC50 | 0.07 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 139 | 833 | 7.5 |
| protein complex format | 52 | 494 | 7.5 |
| tissue-based format | 5 | 19 | 7.4 |
| assay format | 2 | 43 | 7.6 |
| cell-free format | 1 | 33 | 8.0 |
| single protein format | 1 | 35 | 7.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 7 | 136 | 7.8 |
| assay format | 2 | 20 | 7.7 |